Clinical trial NCT00090129: Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Official title: A Multicentre, Randomised, Double-blind, Placebo Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-treatment of Subjects With Moderate to Severe Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Arthritis, Psoriatic
Keywords: Psoriatic Arthritis
Moderate plaque psoriasis
severe plaque psoriasis
Onercept
Placebo
Lead sponsor: EMD Serono
Sponsor class: INDUSTRY
First posted: 2004-08-26
Enrollment: 854
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up (FU) period. The purpose of this study is to evaluate the safety and efficacy of onercept, to be administered as 150 milligram (mg) three times a week, compared to matching placebo, for the induction of remission in subjects with moderate to severe plaque psoriasis.


Eligibility criteria: Inclusion Criteria:

* Written informed consent, given prior to any study-related procedure not part of the subject's normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his or her future medical care
* At least 18 years of age
* Female subjects must be neither pregnant nor breast-feeding, and must lack childbearing potential, as defined by either:

  * Being post-menopausal (that is at least 12 months passed last menses) or surgically sterile, or
  * Using an effective form of contraception (that is, condoms, oral contraceptives or intrauterine device) (Confirmation that the subject is not pregnant must be established by a negative urinary human chorionic gonadotrophin test within 7 days before Study Day 1. A pregnancy test is not required if the subject is post-menopausal or surgically sterile)
* An out-patient status at the time of enrollment
* Plaque psoriasis for at least 12 months
* Plaque psoriasis covering at least 10 percent of total body surface area and a PASI score of 12.0 or more
* Candidate for phototherapy or systemic therapy
* Static Physician's Global Assessment (sPGA) of 3 or more

Exclusion Criteria:

* Use of more than one Non-steroidal anti-inflammatory drug (NSAID) to treat psoriatic arthritis or having a change in chronic NSAID regimen during the 28 days before Study Day 1 to treat psoriatic arthritis
* Previous systemic treatment with biologics, including interferon, and/or cytokines/anti cytokines (for example, anti- tumor necrosis factor-alpha, anti-cluster of differentiation \[CD\]4, interleukin \[IL\]-10, IL-1ra, anti-CD11a, etc.) within 3 months before Study Day 1
* Participation in any other investigational study or experimental therapeutic procedure considered to interfere with the study within 3 months before Study Day 1
* Treatment with any systemic corticosteroids or intra-articular corticosteroid injection during the 28 days before Study Day 1
* Experimental or off-label treatments for psoriasis and/or psoriatic arthritis such as azathioprine, hydroxyurea / hydroxycarbamide, mycophenolate, chlorambucil, leflunomide or cyclophosphamide within 1 year prior to Study Day 1
* Treatment with cyclosporin, methotrexate, oral retinoids (that is, acitretin), or fumaric acid esters within 28 days (3 months for acitretin) before Study Day 1
* Treatment with any topical therapies, such as Vitamin D derivatives, corticosteroids, tars and tar oils, dithranol for chronic or short contact therapy, salicylic acid and topical retinoids, within 14 days before Study Day 1
* Phototherapy within 28 days before Study Day 1
* Use of tanning booths within 14 days before Study Day 1
* Abnormal liver function, defined by a total bilirubin greater than or equal to 1.2 times the upper limit of normal values, (except in the case of Gilbert's syndrome), or aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase levels greater than or equal to 2.5 times the upper limit of normal values
* Inadequate bone marrow reserve, defined as:

  * Leukocytes less than or equal to 3.5 \* 10\^9 per liter (/L), or
  * Thrombocytes less than or equal to 100 \* 10\^9 /L, or
  * Hemoglobin less than or equal to 5 millimole per liter (mmol/L) (8.9 gram per deciliter).
* Abnormal renal function, defined by serum creatinine greater than 150 micromole per liter.
* Sero-positivity for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV)
* Planned major surgery within the treatment period of the study.
* History of cancer in the preceding 5 years (except adequately treated basal cell carcinoma of the skin or squamous cell carcinoma in situ of the skin). Any history of hematopoietic cancer
* History of active tuberculosis, current active tuberculosis or candidacy for prophylactic therapy for tuberculosis
* Active severe infection (or non-severe infection at the discretion of the Investigator).
* History of any opportunistic infection (for example, viral, fungal, protozoal, or bacterial) in the 6 months preceding Study Day 1 related to any clinical condition of immunodeficiency
* Clinically significant and serious abnormalities on electrocardiography or chest X-ray, (at the discretion of the Investigator)
* Other serious concomitant disorders incompatible with the study. In particular, subjects with congestive heart failure, prior or current history of blood dyscrasia or central nervous system demyelinating disorders should not be included in the study
* History of or current drug (including narcotics) abuse, or current active problems with alcohol abuse
* Requirement for immunization, allergy desensitization or vaccination during the entire study period (it is recommended that these procedures be scheduled at least 14 days prior to Study Day 1 or greater than 3 months after the last injection of study drug), with the exception of killed influenza vaccines which are allowed at any time during the study
* Guttate, erythrodermic or pustular psoriasis as sole or predominant form of psoriasis.
* Evidence of skin conditions other than psoriasis (for example, eczema) that would interfere with psoriasis disease assessments
* Clinically significant psoriasis flares during screening or at the time of enrollment necessitating immediate relief (at the Investigator's discretion)
* Live or killed virus or bacteria vaccines (within 14 days before Study Day 1) with the exception of killed influenza vaccines which are allowed both prior to Study Day 1 and at any time during the study
* Bedridden status
* Previous use of onercept

Primary outcomes:
measure: Percentage of subjects with at least a 75 percent improvement in Psoriatic Area and Severity Index (PASI) score at Week 12
timeFrame: Week 12
measure: Percentage of subjects with at least a 75 percent improvement in Psoriatic Area and Severity Index (PASI) score at Week 52
timeFrame: Week 52
Secondary outcomes:
measure: Percentage of subjects attaining a Physician's Global Assessment (PGA) rating of Cleared or Almost Cleared at Week 12
timeFrame: Week 12
measure: Mean percentage improvement in Psoriatic Area and Severity Index (PASI) Score
timeFrame: Baseline up to Week 12
measure: Percentage of subjects with at least a 90 percent improvement in the Psoriatic Area and Severity Index (PASI) score
timeFrame: Baseline up to Week 12
measure: Mean percentage improvement in the itching scale
timeFrame: Baseline up to Week 12
measure: Change from Baseline in Mean improvement of Dermatology Life Quality Index (DLQI) quality of life assessment at Week 12
timeFrame: Baseline and Week 12
measure: Median time to relapse
timeFrame: Week 12 up to Week 36
measure: Percentage of subjects attaining a Physician's Global Assessment (PGA) rating of Cleared or Almost Cleared at Week 52
timeFrame: Week 52
measure: Mean percentage improvement in Psoriatic Area and Severity Index (PASI) Score
timeFrame: Baseline up to Week 48
measure: Mean percentage improvement in Psoriatic Area and Severity Index (PASI) Score up to Week 52
timeFrame: Baseline up to Week 52
measure: Mean Psoriatic Area and Severity Index (PASI) score
timeFrame: Week 36 up to Week 52
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Bressnick Gibson Parker Dinehart Sangster Dermatology, P.A.
state: Arkansas
city: Fresno
country: United States
facility: Associates in Research Inc.
state: California
city: Irvine
country: United States
facility: University of California, Irvine
state: California
city: La Jolla
country: United States
facility: Therapeutics Clinical Research
state: California
city: San Francisco
country: United States
facility: University of California
state: California
city: Santa Monica
country: United States
facility: Clinical Research Specialists Inc.
state: California
city: Vallejo
country: United States
facility: Solano Clinical Research
state: California
city: Vista
country: United States
facility: Dermatology Specialists Inc
state: California
city: Denver
country: United States
facility: Colorado Medical Research Center
state: Colorado
city: Denver
country: United States
facility: Cherry Creek Research, Inc.
state: Colorado
city: Longmont
country: United States
facility: Longmont Clinic PC
state: Colorado
city: New Haven
country: United States
facility: The Savin Center P.C.
state: Connecticut
city: Washington
country: United States
facility: Dermatology Associates, P.C. at the Washington Hospital CTR
state: District of Columbia
city: Jacksonville
country: United States
facility: North Florida Dermatology Associates, P.A.
state: Florida
city: Jacksonville
country: United States
facility: Jacksonville Center for Clinical Research
state: Florida
city: Miami
country: United States
facility: International Dermatology Research
state: Florida
city: Alpharetta
country: United States
facility: Atlanta Dermatology Vein & Research Center
state: Georgia
city: Buffalo Grove
country: United States
facility: Scott D. Glazer, MD
state: Illinois
city: Ann Arbor
country: United States
facility: University of Michigan Department of Dermatology
state: Michigan
city: Clinton Township
country: United States
facility: Midwest Cutaneous Research Corporation
state: Michigan
city: Fridley
country: United States
facility: Minnesota Clinical Study Center
state: Minnesota
city: Albuquerque
country: United States
facility: Academic Dermatology Associates
state: New Mexico
city: Winston Salem
country: United States
facility: Piedmont Medical Research Associates
state: North Carolina
city: Winston Salem
country: United States
facility: Wake Forest Univ School of Medicine
state: North Carolina
city: Portland
country: United States
facility: Northwest Cutaneous Research Specialist
state: Oregon
city: Portland
country: United States
facility: Oregon Medical Research Center, P.C.
state: Oregon
city: Goodlettsville
country: United States
facility: Rivergate Dermatology
state: Tennessee
city: Knoxville
country: United States
facility: Saint Mary's Centeral Wing Annex
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Clinical Research Center
state: Tennessee
city: Austin
country: United States
facility: DermResearch Inc
state: Texas
city: Dallas
country: United States
facility: Texas Dermatology Research Institute
state: Texas
city: Houston
country: United States
facility: Center For Clinical Studies
state: Texas
city: Houston
country: United States
facility: University Texas M.D. Anderson Cancer Center
state: Texas
city: Houston
country: United States
facility: Center for Clinical Studies
state: Texas
city: Norfolk
country: United States
facility: Virginia Clinical Research, Inc
state: Virginia
city: Seattle
country: United States
facility: Dermatology Associates P.L.L.C.
state: Washington
city: Spokane
country: United States
facility: Rockwood Clinic, PS
state: Washington
city: Edmonton
country: Canada
facility: Probity Medical Research
state: Alberta
city: London
country: Canada
facility: Guenther Dermatology Research Center
state: Ontario
city: Waterloo
country: Canada
facility: Probity Medical Research
state: Ontario
Study officials:
References:
citation: Papp K. Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. Curr Med Res Opin. 2010 Oct;26(10):2287-300. doi: 10.1185/03007995.2010.507492.